Biosimilar partnerships and EU approvals surge, enhancing access to innovative treatments in immunology, oncology, and bone ...

Explore the latest developments in the US biosimilar market, highlighting key approvals, challenges, and future trends shaping patient access in 2025.

Explore this year's advancements in gastroenterology biosimilars, highlighting key FDA approvals and market dynamics ...

The most-read ophthalmology biosimilar stories of 2025 included FDA approvals and real-world data. The continued expansion of ...

Explore the latest advancements in denosumab biosimilars, enhancing treatment options for osteoporosis and bone metastases in ...

Biosimilar development costs could plummet from $100 million to $5 million, enabling smaller companies to enter the market ...

In 2025, the latest biosimilar policy developments included bipartisan efforts to enhance affordability and reduce barriers ...

Biosimilars significantly reduce health care costs in Australia, enhancing access to biologics while driving price competition in the pharmaceutical market. The economic impact of biosimilars on the ...

While the Trump administration’s latest executive order touts sweeping drug price cuts through international benchmarking, the broader pharmaceutical pricing crisis in the US reveals a far more ...